We’ve recently updated our valuation analysis.

Alligator Bioscience Valuation

Is ATORX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATORX?

Other financial metrics that can be useful for relative valuation.

ATORX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11x
Enterprise Value/EBITDA-1.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ATORX's PS Ratio compare to its peers?

The above table shows the PS ratio for ATORX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average45.3x
ACOU AcouSort
40.8xn/akr287.1m
NXTCL NextCell Pharma
39.7xn/akr247.2m
MVIR B Medivir
32.7x28.7%kr509.3m
NICA Nanologica
67.9x110.6%kr284.5m
ATORX Alligator Bioscience
16.9x107.8%kr363.3m

Price-To-Sales vs Peers: ATORX is good value based on its Price-To-Sales Ratio (16.9x) compared to the peer average (45.3x).


Price to Earnings Ratio vs Industry

How does ATORX's PE Ratio compare vs other companies in the SE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a47.4%
n/an/an/a

Price-To-Sales vs Industry: ATORX is good value based on its Price-To-Sales Ratio (16.9x) compared to the Swedish Biotechs industry average (19.4x)


Price to Sales Ratio vs Fair Ratio

What is ATORX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATORX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.9x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: ATORX is expensive based on its Price-To-Sales Ratio (16.9x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).


Share Price vs Fair Value

What is the Fair Price of ATORX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATORX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATORX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATORX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentkr1.64
kr3.63
+121.5%
39.1%kr5.60kr2.30n/a3
Nov ’23kr1.45
kr3.63
+150.9%
39.1%kr5.60kr2.30n/a3
Oct ’23kr1.50
kr3.63
+142.9%
39.1%kr5.60kr2.30n/a3
Sep ’23kr1.85
kr3.63
+96.6%
39.1%kr5.60kr2.30n/a3
Aug ’23kr1.75
kr3.63
+107.6%
39.1%kr5.60kr2.30n/a3
Jul ’23kr1.47
kr3.63
+146.8%
39.1%kr5.60kr2.30n/a3
Jun ’23kr1.46
kr3.63
+149.5%
39.1%kr5.60kr2.30n/a3
May ’23kr1.67
kr2.80
+67.5%
7.1%kr3.00kr2.60n/a2
Apr ’23kr2.04
kr2.80
+37.6%
7.1%kr3.00kr2.60n/a2
Mar ’23kr2.29
kr2.80
+22.3%
7.1%kr3.00kr2.60n/a2
Feb ’23kr2.54
kr2.60
+2.6%
0%kr2.60kr2.60n/a1
Jan ’23kr2.57
kr2.60
+1.2%
0%kr2.60kr2.60n/a1
Dec ’22kr2.29
kr2.60
+13.5%
0%kr2.60kr2.60n/a1
Nov ’22kr2.26
kr7.40
+227.4%
0%kr7.40kr7.40kr1.451
Oct ’22kr3.50
kr8.70
+148.9%
14.9%kr10.00kr7.40kr1.502
Sep ’22kr5.40
kr8.70
+61.1%
14.9%kr10.00kr7.40kr1.852
Aug ’22kr5.78
kr8.70
+50.5%
14.9%kr10.00kr7.40kr1.752
Jul ’22kr5.47
kr10.70
+95.6%
30.8%kr14.00kr7.40kr1.472
Jun ’22kr5.40
kr10.70
+98.1%
30.8%kr14.00kr7.40kr1.462
May ’22kr5.80
kr10.70
+84.5%
30.8%kr14.00kr7.40kr1.672
Apr ’22kr6.36
kr12.00
+88.7%
16.7%kr14.00kr10.00kr2.042
Mar ’22kr6.95
kr12.00
+72.7%
16.7%kr14.00kr10.00kr2.292
Feb ’22kr6.40
kr12.00
+87.5%
16.7%kr14.00kr10.00kr2.542
Jan ’22kr7.95
kr12.00
+50.9%
16.7%kr14.00kr10.00kr2.572
Dec ’21kr7.42
kr14.50
+95.4%
26.9%kr19.50kr10.00kr2.293
Nov ’21kr8.09
kr14.50
+79.2%
26.9%kr19.50kr10.00kr2.263

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies